ADMA
ADMA BIOLOGICS, INC.
Overview
ADMA Biologics manufactures and markets plasma-derived immune globulin products for immunodeficient and infection-prone patients.
ADMA BIOLOGICS, INC is a Healthcare company operating in Biotechnology with a $1.99B market cap.
ADMA missed consensus EPS by 0.2% in Q1 FY2026, reported May 6, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-076 Q&A exchanges
- Q4 FY2025Earnings2026-02-255 Q&A exchanges
- Q3 FY2025Earnings2025-11-068 Q&A exchanges
- Q2 FY2025Earnings2025-08-069 Q&A exchanges
- Q1 FY2025Earnings2025-05-078 Q&A exchanges
- Q4 FY2024Earnings2025-03-0313 Q&A exchanges
- Q3 FY2024Earnings2024-11-0720 Q&A exchanges
- Q2 FY2024Earnings2024-08-0812 Q&A exchanges
- Q1 FY2024Earnings2024-05-099 Q&A exchanges
- Q4 FY2023Earnings2024-02-289 Q&A exchanges
- Q3 FY2023Earnings2023-11-0813 Q&A exchanges
- Q2 FY2023Earnings2023-08-098 Q&A exchanges
- Q1 FY2023Earnings2023-05-108 Q&A exchanges
- Q4 FY2022Earnings2023-03-2313 Q&A exchanges
- Q3 FY2022Earnings2022-11-0914 Q&A exchanges
- Q2 FY2022Earnings2022-08-108 Q&A exchanges
- Q1 FY2022Earnings2022-05-118 Q&A exchanges
- Q4 FY2021Earnings2022-03-259 Q&A exchanges
- Q3 FY2021Earnings2021-11-109 Q&A exchanges
- Q2 FY2021Earnings2021-08-117 Q&A exchanges
- Q1 FY2021Earnings2021-05-126 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-06EPS$0.17 vs $0.20-15.3%Rev$114.5M vs ——EODHD
- Q4 FY20252026-03-18EPS$0.22 vs $0.19+15.5%Rev$139.2M vs ——EODHD
- Q3 FY20252025-11-04EPS$0.16 vs $0.160.0%Rev$134.2M vs ——EODHD
- Q2 FY20252025-08-05EPS$0.14 vs $0.15-6.7%Rev$122.0M vs ——EODHD
- Q1 FY20252025-05-06EPS$0.11 vs $0.15-25.0%Rev$114.8M vs ——EODHD
- Q4 FY20242025-02-25EPS$0.14 vs $0.14-6.2%Rev$117.5M vs ——EODHD
- Q3 FY20242024-11-06EPS$0.15 vs $0.13+15.4%Rev$119.8M vs ——EODHD
- Q2 FY20242024-08-07EPS$0.13 vs $0.08+62.5%Rev$107.2M vs ——EODHD
- Q1 FY20242024-05-08EPS$0.08 vs $0.06+33.3%Rev$81.9M vs ——EODHD
- Q4 FY20232024-02-27EPS$-0.08 vs $0.03-100.0%Rev$73.9M vs ——EODHD
- Q3 FY20232023-11-07EPS$0.01 vs $-0.01+100.0%Rev$67.3M vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.03 vs $-0.02-50.0%Rev$60.1M vs ——EODHD
- Q1 FY20232023-05-09EPS$-0.03 vs $-0.04+25.0%Rev$56.9M vs ——EODHD
- Q4 FY20222023-03-22EPS$-0.06 vs $-0.060.0%Rev$50.0M vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.08 vs $-0.080.0%Rev$41.1M vs ——EODHD
- Q2 FY20222022-08-09EPS$-0.07 vs $-0.08+12.5%Rev$33.9M vs ——EODHD
- Q1 FY20222022-05-10EPS$-0.10 vs $-0.08-25.0%Rev$29.1M vs ——EODHD
- Q4 FY20212022-03-23EPS$-0.09 vs $-0.090.0%Rev$26.4M vs ——EODHD
- Q3 FY20212021-11-09EPS$-0.13 vs $-0.14+7.1%Rev$20.7M vs ——EODHD
- Q2 FY20212021-08-10EPS$-0.14 vs $-0.15+6.7%Rev$17.8M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-06 | $0.17 | $0.20 | -15.3% | $114.5M | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $0.22 | $0.19 | +15.5% | $139.2M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $0.16 | $0.16 | 0.0% | $134.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.14 | $0.15 | -6.7% | $122.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.11 | $0.15 | -25.0% | $114.8M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $0.14 | $0.14 | -6.2% | $117.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $0.15 | $0.13 | +15.4% | $119.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $0.13 | $0.08 | +62.5% | $107.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $0.08 | $0.06 | +33.3% | $81.9M | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-0.08 | $0.03 | -100.0% | $73.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $0.01 | $-0.01 | +100.0% | $67.3M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.03 | $-0.02 | -50.0% | $60.1M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.03 | $-0.04 | +25.0% | $56.9M | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-0.06 | $-0.06 | 0.0% | $50.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.08 | $-0.08 | 0.0% | $41.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.07 | $-0.08 | +12.5% | $33.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.10 | $-0.08 | -25.0% | $29.1M | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-0.09 | $-0.09 | 0.0% | $26.4M | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.13 | $-0.14 | +7.1% | $20.7M | — | — | EODHD |
| Q2 FY2021 | 2021-08-10 | $-0.14 | $-0.15 | +6.7% | $17.8M | — | — | EODHD |
Source: EODHD. ADMA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ADMA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.79 | $1.41 | +27.0% | +8.5% | +10.4% |
| Q4 FY2026 | $1.86 | $1.44 | +29.1% | -0.4% | +2.1% |
| Q3 FY2026 | $1.85 | $1.37 | +35.1% | +2.4% | +3.3% |
| Q2 FY2026 | $1.89 | $1.52 | +24.1% | +8.4% | +9.2% |
| Q1 FY2025 | $1.83 | $1.35 | +35.7% | +2.7% | +4.6% |
| Q4 FY2025 | $1.67 | $1.38 | +21.2% | +2.0% | +2.5% |
| Q3 FY2025 | $1.89 | $1.51 | +25.0% | -1.3% | +0.9% |
| Q2 FY2025 | $1.96 | $1.54 | +27.5% | +4.1% | +1.3% |
| Q1 FY2024 | $2.01 | $1.53 | +31.4% | +9.0% | +7.0% |
| Q4 FY2024 | $1.83 | $1.39 | +31.4% | +8.9% | +11.5% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Adam S GrossmanCEO1 yr 3 mo21 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026
- Terry KohlerCFO4 mo1 callCurrentSample
CFO since 2026 • 2/2 beats (100%) • last guidance raise Q2 FY2026
- Brad L TadeCFO1 yr7 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
- Kaitlin M Kestenberg-messinaCOO1 yr 2 mono recorded callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ADMA.
$ curl https://api.spokenalpha.com/v1/companies/ADMAFAQ
Frequently asked about ADMA
Where can I find ADMA BIOLOGICS, INC.'s (ADMA) earnings call transcripts?
Spoken Alpha indexes ADMA's earnings call transcripts at https://spokenalpha.com/companies/ADMA. Each call links to attributed speakers and parsed analyst Q&A. ADMA BIOLOGICS, INC.'s own investor relations page is at https://ir.admabiologics.com/company-info/overview.
When was ADMA BIOLOGICS, INC.'s most recent earnings call?
ADMA BIOLOGICS, INC. (ADMA) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is ADMA in?
ADMA BIOLOGICS, INC. (ADMA) operates in the Healthcare sector (Biotechnology industry).